Outcomes and Complications Post-Allogeneic Hematopoietic Cell Transplantation
A special issue of Hematology Reports (ISSN 2038-8330).
Deadline for manuscript submissions: 31 December 2026 | Viewed by 26
Special Issue Editors
Interests: immune reconstitution; late effects; acute myeloid leukemia (AML); allogeneic stem cell/bone marrow transplant
Special Issue Information
Dear Colleagues,
Allogeneic hematopoietic cell transplantation (HCT) is potentially curative for both benign and malignant hematological disorders, and its use continues to increase worldwide with the expansion of the pool of stem cell donors that are potentially available. Although survival and other outcomes continue to improve over the years with various modifications in practice changes, allogeneic HCT remains associated with significant morbidity and mortality related to numerous potential complications post-transplant. In this Special Issue of Hematology Reports, we invite submissions that explore the complications following allogeneic HCT, analyze factors that influence post-transplant outcomes for a variety of hematological conditions, and shed light into practice changes that may ultimately improve post-transplant outcomes. The Special Issue also welcomes research that explores outcome prediction using novel methods and technologies such as machine learning and biomarker research. Through multidisciplinary contribution, this Special Issue aims to inform best practices and enhance outcomes for allogeneic HCT recipients.
Kind regards,
Dr. Fotios V. Michelis
Dr. Igor Novitzky-Basso
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Hematology Reports is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- allogeneic hematopoietic cell transplantation
- outcomes
- graft-versus-host disease
- relapse
- complications
- immune reconstitution
- late effects
- survivorship
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
